CellSource CoTSE:4880 -2.15%69 Net Margin % is 4.01% as of Apr. 2026, which is 75% below its 10-year median of 15.95. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円781.48 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 938 Biotechnology companies, CellSource Co ranks better than 72.92% on this metric.
Net margin is calculated as Net Income divided by its Revenue. CellSource Co's Net Income for the
six
months ended in Apr. 2026 was 円71 Mil. CellSource Co's Revenue for the
six
months ended in Apr. 2026 was 円1,776 Mil. Therefore, CellSource Co's net margin for the quarter that ended in Apr. 2026 was 4.01%.
The historical rank and industry rank for CellSource Co's Net Margin % or its related term are showing as below:
TSE:4880'
s Net Margin % Range Over the Past 10 Years
Min: 0.29 Med: 15.95 Max: 23.82
Current: 1.93
TSE:4880's Net Margin % is ranked better than 72.92% of 938
companies
in the Biotechnology industry
Industry Median: -88.09
vs TSE:4880: 1.93
CellSource Co (TSE:4880) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
CellSource Co Net Margin % Related Terms
CellSource Co Net Margin % Historical Data
* Premium members only.
The historical data trend for CellSource Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4880 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, CellSource Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where CellSource Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellSource Co (TSE:4880) has a Net Margin % of 4.01% as of Apr. 2026. Net margin is the ratio of total net income to net sales. View historical data on CellSource Co and its competitors. This is 75% below median its historical median of 15.95. Over the past decade, CellSource Co's Net Margin % has ranged from 0.29 to 23.82. According to the industry distribution chart, CellSource Co ranks #254 out of 938 companies in the Biotechnology industry, placing it in the top 27.1%.
Is CellSource Co's Net Margin % too high?
CellSource Co's current Net Margin % of 4.01% is 75% below median its 10-year median of 15.95. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 23.82. Based on the distribution chart, CellSource Co ranks #254 out of 938 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #254 out of 938 companies for Net Margin %. This puts CellSource Co in the upper half of its industry. Historically, CellSource Co's own Net Margin % has ranged from 0.29 to 23.82 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on CellSource Co and its competitors. CellSource Co's current Net Margin % is 4.01%, which is 75% below median its own 10-year median of 15.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円781.48, compared to a current price of 円319.00 — trading 59.2% below its estimated fair value. The current Net Margin % is 4.01%, which is 75% below median its 10-year median of 15.95. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current Net Margin % is 4.01% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円319.00 is trading 59.2% below its estimated GF Value™ of 円781.48.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
Net Margin %: 4.01% (75% below median its 10-year median of 15.95)
GF Value™: 円781.48 vs. price of 円319.00 (59.2% below fair value)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score
Get the complete analysis for TSE:4880
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
